Business Update Positive

2026-11-04 22:02

Alembic Pharmaceuticals received USFDA final approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). - The approved product has an estimated US market size of $20 million for the twelve months ending September 2026. - Developed in collaboration with Orbicular Pharmaceutical Technologies Pvt Ltd. - Total cumulative ANDA approvals for Alembic now stand at 248.

Routine Neutral

2026-11-04 19:11

- Alembic Pharmaceuticals Limited has submitted the audio recording of its Post Results Conference Call held on 4th November, 2026. - The audio recording is accessible on the company's website.

Governance Neutral

2026-11-04 15:17

- Alembic Pharmaceuticals Limited has updated the contact details of its Key Managerial Personnel pursuant to Regulation 30(5) of SEBI (LODR) Regulations, 2015. - Authorized KMPs include Mr. Chirayu Amin (Executive Chairman), Mr. Pranav Amin (Managing Director), Mr. Shaunak Amin (Managing Director), and Mr. G. Krishnan (Chief Financial Officer) for determining materiality and making disclosures. - Mr. Chirag K. Shukla (Company Secretary) is authorized to make disclosures to stock exchanges.

Business Update Positive

2026-11-04 14:44

- Q2 FY27 Revenue grew 36% YoY to ₹26.03 bn - EBITDA surged 78% YoY to ₹5.78 bn; EBITDA margin expanded 520 bps - PAT rose 81% YoY to ₹3.35 bn - US formulations jumped 77% YoY to ₹10.03 bn; India Branded business grew 14% YoY to ₹7.25 bn

Business Update Positive

2026-11-04 14:44

Alembic Pharmaceuticals expanded its strategic collaboration with DifGen Pharmaceuticals to enhance its complex generics portfolio in the US. - The partnership covers a portfolio of 20+ differentiated products across injectables, transdermals, ophthalpics, and oral dosage forms, addressing a ~US$5 billion reference market. - Initial product launches are expected from FY28, providing near-term revenue visibility. - DifGen will lead development, regulatory, and US manufacturing activities, while Alembic will commercialize the portfolio and manufacture select products.

Business Update Positive

2026-11-04 14:39

- Q2 FY27 Consolidated Revenue grew 36% YoY to ₹2,603 Cr. - EBITDA increased 78% YoY to ₹578 Cr with margins at 22%. - Profit After Tax jumped 81% YoY to ₹335 Cr. - US Formulations surged 77% to ₹1,003 Cr; India Branded grew 14% to ₹725 Cr.

Routine Neutral

2026-11-04 14:35

New Filing detected. See link for details.

Financials Positive

2026-11-04 14:33

Q2 FY27 Consolidated Revenue ₹2,603.48Cr vs ₹1,910.15Cr (▲36% YoY) EBITDA ₹561.90Cr vs ₹317.11Cr (▲77% YoY) PAT ₹335.17Cr vs ₹184.71Cr (▲81% YoY) EBITDA Margin 21.58% vs 16.60% (▲498bps)

Business Update Neutral

2026-11-02 20:49

Concall Schedule Concall Date: 4th November, 2026 Concall Time: 5:00 P.M. Updated link provided for the Post Results Conference Call with unchanged dial-in numbers.

Governance Neutral

2026-10-30 19:24

- Alembic Pharmaceuticals Limited has informed the Exchange about the rescheduling of a meeting. - Further details regarding the rescheduled meeting date and time will be provided in due course.

Business Update Positive

2026-10-30 18:34

- Alembic Pharmaceuticals received USFDA final approval for Venetoclax Tablets, 10 mg, 50 mg, and 100 mg. - The product is therapeutically equivalent to AbbVie's Venclexta Tablets, used for chronic lymphocytic leukemia, small lymphocytic lymphoma, and acute myeloid leukemia. - Alembic was a first ANDA applicant with a paragraph IV certification and may be eligible for 180 days of generic drug exclusivity. - The estimated US market size for Venetoclax tablets was US $1,584 million for the twelve months ending June 2026. - With this approval, Alembic has a cumulative total of 248 USFDA ANDA approvals.

Business Update Neutral

2026-10-28 15:50

Concall Schedule Concall Date: 4th November, 2026 Concall Time: 4:00 P.M. IST

Business Update Positive

2026-10-27 15:33

Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. - The approved product is therapeutically equivalent to Valcyte for Oral Solution. - The drug is indicated for the treatment of CMV retinitis in AIDS patients and prevention of CMV disease in transplant patients. - With this approval, the company's cumulative USFDA ANDA approvals stand at 247.

Business Update Neutral

2026-10-19 19:22

- Alembic Global Holding SA, a wholly-owned subsidiary of Alembic Pharmaceuticals Limited, has incorporated a step-down wholly-owned subsidiary named Alvesta Pharmaceuticals FZCO in Dubai, United Arab Emirates, on 1st September, 2026. - The new entity operates in the pharmaceuticals sector and was established with a cash consideration of AED 100,000 for 100% shareholding control to explore new business opportunities and distribute pharmaceutical products.

Business Update Positive

2026-10-17 18:58

Alembic Pharmaceuticals received USFDA final approval for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%. - The approved product is therapeutically equivalent to Sandoz's Ciprodex Otic Suspension. - Estimated market size in the US is US$110 million for the twelve months ending June 2026. - Alembic now has a cumulative total of 246 USFDA ANDA approvals.

Routine Neutral

2026-09-28 18:27

- Trading window closure for dealing in company securities begins from 1st October, 2026. - Closure remains effective until 48 hours after declaration of Unaudited Financial Results for the quarter and half-year ending 30th September, 2026.

Business Update Neutral

2026-09-18 17:30

- Investor/Analyst Meeting Schedule - Meeting Date: 23rd September, 2026 - Meeting Time: 10:00 AM onwards - Type: One-to-one meetings with institutional investors/analysts

Business Update Positive

2026-09-16 18:10

- USFDA has issued an Establishment Inspection Report (EIR) for Alembic Pharmaceuticals' Bioequivalence Facility in Vadodara, Gujarat. - The inspection, conducted from March 3-7, 2025, has been closed.

Business Update Positive

2026-09-11 11:38

- Alembic Pharmaceuticals Limited successfully completed an unannounced USFDA onsite Bioequivalence inspection at its Vadodara facility. - The inspection concluded with no Form 483 observations. - The inspection was conducted from August 31, 2026, to September 10, 2026.

Business Update Positive

2026-09-07 20:37

- Alembic Pharmaceuticals Limited incorporated a Wholly Owned Subsidiary (WOS), Alembic Pharmaceuticals Global FZCO, in Dubai, UAE on August 24, 2026. - The WOS aims to explore new business opportunities and to promote, sell, and distribute pharmaceutical products. - The total subscription cost for 100% shareholding is AED 100,000.

Business Update Neutral

2026-08-27 16:27

- Investor/Analyst Meetings Schedule - Dates: September 01, 2026 and September 02, 2026 - Participants include Dolat Capital, Equirus Securities, 360 ONE Capital, ICICI Securities, Ashmore (Fund), HSBC, BOB Capital Markets Itd, Nirmal Bang, and Yes Securities. - Meetings will be In-Person (Mumbai) and Virtual. - No Unpublished Price Sensitive Information (UPSI) will be shared during the meetings.

Business Update Neutral

2026-08-27 16:27

- Investor/Analyst Meetings Schedule - Dates: September 01, 2026 and September 02, 2026 - Meetings with: Dolat Capital, Equirus Securities, 360 ONE Capital, ICICI Securities, Ashmore (Fund), HSBC, BOB Capital Markets Itd, Nirmal Bang, Yes Securities - Format: In-person (Mumbai) and Virtual - No Unpublished Price Sensitive Information will be shared.

Governance Neutral

2026-08-20 19:03

- Mr. Chirag Shukla has been appointed as Company Secretary & Compliance Officer (Key Managerial Personnel). - The appointment is effective from August 20, 2026. - He is a qualified Company Secretary and Law Graduate with over 19 years of experience.

Governance Negative

2026-08-10 19:05

CRITICAL RED FLAG DETECTED

- Ms. Manisha Saraf resigned from the position of Company Secretary & Compliance Officer (Key Managerial Personnel) and Nodal Officer. - Her resignation is effective from 10th August, 2026, to pursue a new opportunity for career growth and development.

Business Update Positive

2026-08-10 12:55

- FY27 overall growth outlook improved from low double-digit to mid-teen range. - US business growth outlook revised up to mid to high teens for FY27. - API segment expected to grow above 10% for the year. - India Human Health business expected to show positive trends in the next couple of quarters, aiming for high single-digit to low double-digit growth. - US Branded Specialty business expected to contribute positively to profit from FY28. - EBITDA margin trajectory broadly reflects operating leverage, with core margins improving to high-teens, partially offset by US branded investments (~150bps dilution). - Gross debt of ~INR1,600 crores expected to moderate in Q2/Q3, returning to March levels and aiming for ~1x EBITDA. - Planning to launch another 15 products for the rest of FY27.

Governance Positive

2026-08-05 18:51

- Proceedings of the 16th Annual General Meeting held on August 5, 2026. - Adopted FY26 financial statements and declared dividend for FY26. - Re-appointed Mr. Pranav Amin and appointed Mr. Sujit Bhayani as Independent Director. - Voting results to be declared by August 7, 2026.

Business Update Neutral

2026-08-04 19:30

- Alembic Pharmaceuticals Limited has submitted the audio recording of its Post Results Conference Call held on August 4, 2026. - The recording is available on the company's website at alembicpharmaceuticals.com/quarterly-results.

Financials Positive

2026-08-04 14:54

- Consolidated Revenue ₹2,150 Cr vs ₹1,711 Cr (▲26% YoY) - EBITDA ₹523 Cr vs ₹432 Cr (▲21% YoY) - PAT ₹173 Cr vs ₹154.5 Cr (▲12% YoY) - EBITDA Margin 24% vs 25.3% (▼130bps)

Financials Positive

2026-08-04 14:21

- Consolidated Revenue ₹2150 Cr vs ₹1711 Cr (▲26% YoY) - EBITDA ₹523 Cr vs ₹432 Cr (▲21% YoY) - PAT ₹173 Cr vs ₹154 Cr (▲12% YoY) - EBITDA Margin 24% vs 25.3% (▼130bps)

Financials Positive

2026-08-04 14:12

- Consolidated Revenue ₹2,149.77 Cr vs ₹1,710.72 Cr (▲25.66% YoY) - EBITDA ₹332.25 Cr vs ₹280.89 Cr (▲18.28% YoY) - PAT ₹175.33 Cr vs ₹155.09 Cr (▲13.05% YoY) - EBITDA Margin 16.18% vs 16.84% (▼66bps)

Financials Positive

2026-08-04 14:06

- Consolidated Revenue ₹2,149.77 Cr vs ₹1,710.72 Cr (▲25.66% YoY) - EBITDA ₹347.88 Cr vs ₹287.97 Cr (▲20.80% YoY) - PAT ₹172.36 Cr vs ₹153.64 Cr (▲12.19% YoY) - EBITDA Margin 16.18% vs 16.84% (▼66 bps)

APLLTD

Alembic Pharmaceuticals Limited

Price Chart

Filing History

Unlock Full History